Xencor Inc. Aktie
21,80 €
Deine Einschätzung
Xencor Inc. Aktie
Was spricht für und gegen Xencor Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Xencor Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Xencor Inc. | 2,83 % | -0,93 % | 7,61 % | -15,87 % | 10,99 % | -33,14 % | -24,42 % |
Ironwood Pharmaceuticals | -0,90 % | 0,00 % | -23,45 % | -45,05 % | -45,59 % | -41,27 % | - |
Novocure Ltd | -0,58 % | -0,39 % | 79,26 % | -68,94 % | 44,10 % | -87,70 % | - |
Iovance Biotherapeutics Inc. | -0,55 % | -12,62 % | -24,76 % | 0,63 % | 6,38 % | -45,52 % | - |
Kommentare
News
Xencor Reports First Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company